Trial Profile
Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Daunorubicin (Primary) ; Nilotinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NICE-BORA
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Status changed from recruiting to discontinued.
- 10 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.